{"id":16918,"date":"2021-09-01T13:42:11","date_gmt":"2021-09-01T00:42:11","guid":{"rendered":"https:\/\/clladvocates.nz\/?p=16918"},"modified":"2021-09-02T21:23:53","modified_gmt":"2021-09-02T08:23:53","slug":"an-expert-hematologist-oncologist-highlights","status":"publish","type":"post","link":"https:\/\/clladvocates.nz\/?p=16918","title":{"rendered":"An expert hematologist\/oncologist highlights"},"content":{"rendered":"

[vc_row row_height_percent=”0″ override_padding=”yes” h_padding=”2″ top_padding=”3″ bottom_padding=”3″ overlay_alpha=”50″ gutter_size=”3″ column_width_percent=”100″ shift_y=”0″ z_index=”0″][vc_column column_width_percent=”100″ gutter_size=”3″ overlay_alpha=”50″ shift_x=”0″ shift_y=”0″ shift_y_down=”0″ z_index=”0″ medium_width=”0″ mobile_width=”0″ width=”1\/1″][vc_custom_heading heading_semantic=”h1″ text_size=”h1″ uncode_shortcode_id=”137034″]<\/p>\n

An expert hematologist\/oncologist highlights<\/em><\/h1>\n

[\/vc_custom_heading][vc_column_text uncode_shortcode_id=”106733″]This article was originally published on OncLive<\/a><\/p>\n

\n
\n
\n
\n
Future of CLL Management<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
\n
<\/div>\n<\/div>\n
\n

Tara Graff, DO, MS:<\/strong>\u00a0If somebody asked me the most important things to do with a newly diagnosed patient with CLL [chronic lymphocytic leukemia], first and foremost\u2014I can\u2019t say this enough\u2014it\u2019s so important to check all the different genomic aberrations. You need to know. We\u2019re always used to, \u201c13q, they\u2019ve got great disease, they\u2019re never going to need treatment.\u201d But that\u2019s a knee-jerk reaction. It\u2019s important to know that, but there are so many other molecular aberrations that we need to know about, specifically 17p,\u00a0TP53<\/em>, and the\u00a0IGHV<\/em>\u00a0mutational status. We need to know that. Looking back, when I\u2019ve picked up patients who may have been seen by another provider, those weren\u2019t checked. We could have potentially done them a disservice in the past if we gave FCR [fludarabine, cyclophosphamide, rituximab] to a patient who had an unmutated\u00a0IGHV<\/em>. They have a really poor response to chemotherapy-immunotherapy, but we didn\u2019t always know that. That wasn\u2019t always being tested routinely.<\/p>\n<\/div>\n

To continue reading this article on OncLive<\/a>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

An expert hematologist\/oncologist highlights key takeaways for the future management of chronic lymphocytic leukemia given an evolving therapeutic landscape.<\/p>\n","protected":false},"author":1,"featured_media":16919,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[12],"tags":[],"class_list":["post-16918","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-media"],"jetpack_featured_media_url":"https:\/\/clladvocates.nz\/wp-content\/uploads\/2021\/09\/CLL-1-09-2021.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/16918","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=16918"}],"version-history":[{"count":1,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/16918\/revisions"}],"predecessor-version":[{"id":16920,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/16918\/revisions\/16920"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/media\/16919"}],"wp:attachment":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=16918"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=16918"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=16918"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}